The present invention relates to the cosmetic and/or nutraceutical use of an extract of the Lythrum salicaria plant and/or of gallic acid and/or one of the gallic acid derivatives, in particular vescalagin and/or castalagin, more preferentially castalagin, for maintaining and/or increasing collagen expression in the skin and/or the mucous membranes for maintaining and/or increasing the firmness of the skin and/or the mucous membranes and/or for maintaining and/or increasing lipolysis in skin adipocytes for inducing a slimming effect onto the skin and/or for decreasing, preventing and/or treating the unaesthetic manifestations of cellulite, for example the orange peel appearance of the skin and/or the jodhpur thigh appearance.

Another subject of the invention relates to a cosmetic care process comprising the application, preferably topically, of the Lythrum salicaria extract according to the invention and/or of gallic acid and/or of one of the gallic acid derivatives, in particular vescalagin and/or castalagin, more preferentially castalagin, or of a cosmetic composition comprising it, for maintaining and/or increasing collagen expression in the skin and/or the mucous membranes for increasing the firmness of the skin and/or of the mucous membranes and/or maintaining and/or increasing lipolysis in skin adipocytes for inducing a slimming effect onto the skin and/or decreasing, preventing and/or treating the unaesthetic manifestations of cellulite, for example the orange peel appearance of the skin and/or the jodhpur thigh appearance.

The present invention relates to the cosmetic and/or nutraceutical use of an extract of the Lythrum salicaria plant and/or of gallic acid and/or one of the gallic acid derivatives, in particular vescalagin and/or castalagin, more preferentially castalagin, for maintaining and/or increasing collagen expression in the skin and/or the mucous membranes for maintaining and/or increasing the firmness of the skin and/or the mucous membranes and/or for maintaining and/or increasing lipolysis in skin adipocytes for inducing a slimming effect onto the skin and/or for decreasing, preventing and/or treating the unaesthetic manifestations of cellulite, for example the orange peel appearance of the skin and/or the jodhpur thigh appearance.

Another subject of the invention relates to a cosmetic care process comprising the application, preferably topically, of the Lythrum salicaria extract according to the invention and/or of gallic acid and/or of one of the gallic acid derivatives, in particular vescalagin and/or castalagin, more preferentially castalagin, or of a cosmetic composition comprising it, for maintaining and/or increasing collagen expression in the skin and/or the mucous membranes for increasing the firmness of the skin and/or of the mucous membranes and/or maintaining and/or increasing lipolysis in skin adipocytes for inducing a slimming effect onto the skin and/or decreasing, preventing and/or treating the unaesthetic manifestations of cellulite, for example the orange peel appearance of the skin and/or the jodhpur thigh appearance.

The present invention relates to the use by oral route of a composition for oral administration comprising at least one probiotic and at least one B group vitamin, for improvement the cellulite appearance of skin.

The present invention relates to the use by oral route of a composition for oral administration comprising at least one probiotic and at least one B group vitamin, for improvement the cellulite appearance of skin.

An optimized nutrient fatty acid composition capable of using as food, skin care, hair care and media for delivery of drugs and nutrients through mucous membrane, skin and parenterally for humans, pets and farm animals, with a ratio of omega 6 fatty acid to omega 3 fatty acids ranging from 1:1 to 1:1.25 stabilized with vitamin E 0.8-4 mg/ml. More specifically a stable fatty acid composition with 50-70% of the total fatty acids as essential and, or semi essential fatty acid of which 25-35% omega 3 fatty acids, 25-35% as omega 6 fatty acids and 20-30% as monounsaturated fatty acids is capable of optimization of bodily functions, maintenance of health, prevention of diseases, promotion of healing, delay aging, and treatment of diseases caused by imbalance in omega 3 and 6 fatty acid ratio in diet and nutritional support for pregnant and lactating women, growing children, senior citizens, sports persons, obese and over weight on calorie restricted diet.

An optimized nutrient fatty acid composition capable of using as food, skin care, hair care and media for delivery of drugs and nutrients through mucous membrane, skin and parenterally for humans, pets and farm animals, with a ratio of omega 6 fatty acid to omega 3 fatty acids ranging from 1:1 to 1:1.25 stabilized with vitamin E 0.8-4 mg/ml. More specifically a stable fatty acid composition with 50-70% of the total fatty acids as essential and, or semi essential fatty acid of which 25-35% omega 3 fatty acids, 25-35% as omega 6 fatty acids and 20-30% as monounsaturated fatty acids is capable of optimization of bodily functions, maintenance of health, prevention of diseases, promotion of healing, delay aging, and treatment of diseases caused by imbalance in omega 3 and 6 fatty acid ratio in diet and nutritional support for pregnant and lactating women, growing children, senior citizens, sports persons, obese and over weight on calorie restricted diet.

The invention provides fused heterocyclic organic compounds such as dihydropyrazolopyridotriazinones, compositions containing such compounds, medical kits, and methods for using such compounds and compositions for body contouring and/or reduction of fat in a subject.

The invention provides fused heterocyclic organic compounds such as dihydropyrazolopyridotriazinones, compositions containing such compounds, medical kits, and methods for using such compounds and compositions for body contouring and/or reduction of fat in a subject.

The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.

Provided are a reelin and/or VEGF-C production and/or activation promoter including a compound represented by Chemical Formula 1 or a salt thereof as an active ingredient, and a skin external composition including the same.

##STR00001##

(In Chemical Formula 1, each substituent is as defined in the specification.)